Title: Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.
Journal: Veterinary and comparative oncology 20120901
Title: Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
Journal: Veterinary and comparative oncology 20120901
Title: Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib.
Journal: Veterinary and comparative oncology 20120901
Title: Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
Journal: Veterinary and comparative oncology 20120901
Title: Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
Journal: Veterinary and comparative oncology 20120901
Title: Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.
Journal: Journal of veterinary internal medicine 20120101
Title: Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
Journal: Journal of veterinary internal medicine 20120101
Title: Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
Journal: Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association 20120101
Title: Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.
Journal: Veterinary and comparative oncology 20100901
Title: Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs.
Journal: Journal of veterinary pharmacology and therapeutics 20100401
Title: Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Journal: Journal of veterinary pharmacology and therapeutics 20100401
Title: Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090601
Title: Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20031115
Title: Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20030701
Title: Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.
Journal: Blood 20020715
Title: London CA, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003 Jul;9(7):2755-68.
Title: Halsey CH, et al. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia?) in canine mast cell tumor. BMC Vet Res. 2014 May 6;10:105.
Title: Mitchell L, et al. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med. 2012 Mar-Apr;26(2):355-62.
